Today's Research Reports on Stocks to Watch: Abbott Laboratories and Pfizer Inc.
NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Abbott Laboratories saw its shares climb higher yesterday after announcing Q2 results that narrowly beat Wall Street's expectations. Shares of Pfizer saw a loss after it was revealed that the pharmaceutical giant is facing two patent expirations, for Viagra, and Lyrica, two drugs that accounted for 4.2 billion or more in domestic sales in 2016.
RDI Initiates Coverage on:
Abbott Laboratories
https://ub.rdinvesting.com/news/?ticker=ABT
Pfizer Inc.
https://ub.rdinvesting.com/news/?ticker=PFE
Abbott Laboratories shares closed up 2.87% yesterday and hit a new high of $51.13. Volume for the stock was also nearly double compared to usual. So why was the stock near its all-time new high? The American worldwide health care company reported its second quarter financial results and both profits and revenue narrowly topped what analysts had been expecting. For the second quarter ended June 30th, the company reported income of 62 cents a share. Wall Street had been looking for 60 cents a share. The medical giant also increased its forecast for 2017 profits from $2.43 to $2.53. According to RBC analyst Glenn Novarro, analysts had called for $2.47 earnings per share. RBC has an "outperform" rating on the stock.
Access RDI's Abbott Laboratories Research Report at:
https://ub.rdinvesting.com/news/?ticker=ABT
Pfizer Inc. shares closed down a modest 0.24% on Thursday with nearly 17 million shares traded. It was a bad news day for the company. According to analysts at Credit Suisse, Pfizer is looking at not one, but two patent expirations for its male impotency treatment drug Viagra and its drug Lyrica, which treats nerve damage. The patents were described as "meaningful." Analyst Vamil Divan stated, "We have been long-time supporters of the PFE story and see opportunities for upside over the long-term, but see more limited drivers of upside over the next 6-12 months." Divan expects Pfizer to lose the U.S. patent exclusively for Viagra in December of this year and to lose the patent for Lyrica next year. He reduced his earnings per share targets for next year to $2.71 from $2.78. He also cut his price target on the stock from $38 to $36.
Access RDI's Pfizer Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=PFE
Our Actionable Research on Abbott Laboratories (NYSE: ABT) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
